These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 26782312)

  • 21. Efficacy of natalizumab in second line therapy of relapsing-remitting multiple sclerosis: results from a multi-center study in German speaking countries.
    Putzki N; Yaldizli O; Mäurer M; Cursiefen S; Kuckert S; Klawe C; Maschke M; Tettenborn B; Limmroth V
    Eur J Neurol; 2010 Jan; 17(1):31-7. PubMed ID: 19614963
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Are natalizumab and fingolimod analogous second-line options for the treatment of relapsing-remitting multiple sclerosis? A clinical practice observational study.
    Gajofatto A; Bianchi MR; Deotto L; Benedetti MD
    Eur Neurol; 2014; 72(3-4):173-80. PubMed ID: 25226868
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term disease activity and disability progression in relapsing-remitting multiple sclerosis patients on natalizumab.
    Dekker I; Leurs CE; Hagens MHJ; van Kempen ZLE; Kleerekooper I; Lissenberg-Witte BI; Barkhof F; Uitdehaag BMJ; Balk LJ; Wattjes MP; Killestein J
    Mult Scler Relat Disord; 2019 Aug; 33():82-87. PubMed ID: 31174043
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A validation study of manual atrophy measures in patients with Multiple Sclerosis.
    Cappelle S; Pareto D; Tintoré M; Vidal-Jordana A; Alyafeai R; Alberich M; Sastre-Garriga J; Auger C; Montalban X; Rovira À
    Neuroradiology; 2020 Aug; 62(8):955-964. PubMed ID: 32246177
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Improvement of quality of life and its relationship with neuropsychiatric outcomes in patients with multiple sclerosis starting treatment with natalizumab: A 3-year follow-up multicentric study.
    Planche V; Moisset X; Morello R; Dumont E; Gibelin M; Charré-Morin J; Saubusse A; Mondou A; Reuter F; Defer G; Pelletier J; Brochet B; Clavelou P
    J Neurol Sci; 2017 Nov; 382():148-154. PubMed ID: 29111011
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term assessment of No Evidence of Disease Activity with natalizumab in relapsing multiple sclerosis.
    Prosperini L; Fanelli F; Pozzilli C
    J Neurol Sci; 2016 May; 364():145-7. PubMed ID: 27084235
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Extensive brain demyelinating lesions under natalizumab: The role of anti-natalizumab antibodies.
    Debs R; Maillart E; Fahed R; Papeix C; Duyckaerts C; Stadelmann C; Galanaud D; Lubetzki C
    Neurology; 2015 Nov; 85(18):1630-2. PubMed ID: 26453649
    [No Abstract]   [Full Text] [Related]  

  • 28. Erythroblastaemia in natalizumab-treated patients with multiple sclerosis.
    La Gioia S; Seghezzi M; Barcella V; Dominoni P; Mecca T; Frigeni B; Conti MZ; Vedovello M; Vidali M; Rottoli M; Buoro S
    Mult Scler Relat Disord; 2016 Jul; 8():141-4. PubMed ID: 27456890
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Increased relapse activity for multiple sclerosis natalizumab users who become nonpersistent: a retrospective study.
    McQueen RB; Livingston T; Vollmer T; Corboy J; Buckley B; Allen RR; Nair K; Campbell JD
    J Manag Care Spec Pharm; 2015 Mar; 21(3):210-8b. PubMed ID: 25726030
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Incorporating real-world clinical practice in multiple sclerosis economic evaluations.
    McQueen RB; Nair KV; Vollmer TL; Campbell JD
    Expert Rev Pharmacoecon Outcomes Res; 2015; 15(6):869-72. PubMed ID: 26295727
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Brain Atrophy in Natalizumab-treated Patients with Multiple Sclerosis: A 5-year Retrospective Study.
    Eisele P; Szabo K; Ebert A; Platten M; Gass A
    J Neuroimaging; 2019 Mar; 29(2):190-192. PubMed ID: 30485572
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Corpus callosum atrophy--a simple predictor of multiple sclerosis progression: a longitudinal 9-year study.
    Vaneckova M; Kalincik T; Krasensky J; Horakova D; Havrdova E; Hrebikova T; Seidl Z
    Eur Neurol; 2012; 68(1):23-7. PubMed ID: 22677920
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Natalizumab may reduce cognitive changes and brain atrophy rate in relapsing-remitting multiple sclerosis--a prospective, non-randomized pilot study.
    Portaccio E; Stromillo ML; Goretti B; Hakiki B; Giorgio A; Rossi F; De Leucio A; De Stefano N; Amato MP
    Eur J Neurol; 2013 Jun; 20(6):986-90. PubMed ID: 23057658
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Disease-modifying therapies modulate retinal atrophy in multiple sclerosis: A retrospective study.
    Button J; Al-Louzi O; Lang A; Bhargava P; Newsome SD; Frohman T; Balcer LJ; Frohman EM; Prince J; Calabresi PA; Saidha S
    Neurology; 2017 Feb; 88(6):525-532. PubMed ID: 28077493
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Modulation of Retinal Atrophy With Rituximab in Multiple Sclerosis.
    Lambe J; Risher H; Filippatou AG; Murphy OC; Sotirchos ES; Ehrhardt H; Ogbuokiri E; Pellegrini N; Toliver B; Luciano NJ; Davis S; Fioravante N; Kwakyi O; Prince JL; Calabresi PA; Fitzgerald KC; Saidha S
    Neurology; 2021 May; 96(20):e2525-e2533. PubMed ID: 33827962
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Natalizumab plus interferon beta-1a reduces lesion formation in relapsing multiple sclerosis.
    Radue EW; Stuart WH; Calabresi PA; Confavreux C; Galetta SL; Rudick RA; Lublin FD; Weinstock-Guttman B; Wynn DR; Fisher E; Papadopoulou A; Lynn F; Panzara MA; Sandrock AW;
    J Neurol Sci; 2010 May; 292(1-2):28-35. PubMed ID: 20236661
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cognitive function did not improve after initiation of natalizumab treatment in relapsing-remitting multiple sclerosis. A prospective one-year dual control group study.
    Sundgren M; Piehl F; Wahlin Å; Brismar T
    Mult Scler Relat Disord; 2016 Nov; 10():36-43. PubMed ID: 27919496
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Enhanced axonal metabolism during early natalizumab treatment in relapsing-remitting multiple sclerosis.
    Wiebenga OT; Klauser AM; Schoonheim MM; Nagtegaal GJ; Steenwijk MD; van Rossum JA; Polman CH; Barkhof F; Pouwels PJ; Geurts JJ
    AJNR Am J Neuroradiol; 2015 Jun; 36(6):1116-23. PubMed ID: 25742985
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Natalizumab is effective as second line therapy in the treatment of relapsing remitting multiple sclerosis.
    Putzki N; Kollia K; Woods S; Igwe E; Diener HC; Limmroth V
    Eur J Neurol; 2009 Mar; 16(3):424-6. PubMed ID: 19187261
    [TBL] [Abstract][Full Text] [Related]  

  • 40. MRI-based analysis of the natalizumab therapeutic window in multiple sclerosis.
    Grimaldi LM; Prosperini L; Vitello G; Borriello G; Fubelli F; Pozzilli C
    Mult Scler; 2012 Sep; 18(9):1337-9. PubMed ID: 22389413
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.